$AZN Market Cap:
Research Board Inbox Deep Research Not Interested Shortlisted

$AZN SEC Filings

Filing Filed On
ENHERTU GRANTED ORPHAN DRUG DESIGNATION IN THE US FOR GASTRIC CANCER 22 May 2020
ASTRAZENECA ADVANCES RESPONSE TO GLOBAL COVID-19 CHALLENGE AS IT RECEIVES FIRST 21 May 2020
LYNPARZA APPROVED IN THE US FOR HRR GENE-MUTATED METASTATIC CASTRATION-RESISTANT 20 May 2020
BEVESPI AEROSPHERE APPROVED IN CHINA FOR COPD 18 May 2020
ENHERTU US BREAKTHROUGH STATUS FOR LUNG CANCER 18 May 2020
LYNPARZA APPROVED IN THE US AS 1ST-LINE MAINTENANCE TREATMENT WITH BEVACIZUMAB F 11 May 2020
ASTRAZENECA RECOVERY OF GLOBAL RIGHTS TO BRAZIKUMAB (MEDI2070) FROM ALLERGAN COM 11 May 2020
ENHERTU GRANTED BREAKTHROUGH THERAPY DESIGNATION IN THE US FOR HER2-POSITIVE MET 11 May 2020
FARXIGA APPROVED IN THE US FOR THE TREATMENT OF HEART FAILURE IN PATIENTS WITH H 06 May 2020
TOTAL VOTING RIGHTS 01 May 2020
AZN: FIRST-QUARTER 2020 RESULTS 29 Apr 2020
RESULT OF AGM 29 Apr 2020
LYNPARZA DEMONSTRATED OVERALL SURVIVAL BENEFIT IN PHASE III PROFOUND TRIAL FOR B 24 Apr 2020
CHANGES TO ARRANGEMENTS FOR ANNUAL GENERAL MEETING 17 Apr 2020
TAGRISSO PHASE III ADAURA TRIAL WILL BE UNBLINDED EARLY AFTER OVERWHELMING EFFIC 14 Apr 2020
KOSELUGO (SELUMETINIB) APPROVED IN US FOR PAEDIATRIC PATIENTS WITH NEUROFIBROMAT 14 Apr 2020
ASTRAZENECA DIVESTMENT OF MOVANTIK TO REDHILL BIOPHARMA COMPLETED 02 Apr 2020
TOTAL VOTING RIGHTS 01 Apr 2020
DIRECTOR/PDMR SHAREHOLDING 31 Mar 2020
IMFINZI APPROVED IN THE US FOR EXTENSIVE-STAGE SMALL CELL LUNG CANCER 30 Mar 2020